Is the pharmaceutical industry responding to the challenge of increasing bacterial resistance?

Clinical Microbiology Newsletter

Volumn 28, Issue 2, 2006, Pages 13-15

  Poupard, James A ^a  

^a Pharma Institute of Philadelphia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOTECHNOLOGY; CROSS RESISTANCE; DRUG INDUSTRY; DRUG RESEARCH; ECONOMIC ASPECT; GENOMICS; GOVERNMENT;

EID: 29844440176     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2005.12.008     Document Type: Article

References (9)

1. White A.R. The pharmaceutical company approach to antibiotic policies I.M. Gould J.M. Van Der Meer Antibiotic policies 2005 Plenum Publishers New York 673 699
2. Fraser C.M. An uncertain call to arms Science 304 2004 359
3. Infectious Diseases Society of America White paper report. Bad bugs, no drugs: as antibiotic discovery stagnatesé a public health crisis brews http://www.idsociety.org 2004 (online.)
4. Szuromi P., Vinson V., E. Marshall Rethinking drug discovery Science 303 2004 1795
5. Wenzel R.P. The antibiotic pipeline - challenges, costs and values N. Engl. J. Med. 351 2004 523 526
6. Projan S.J. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6 2003 427 430
7. Coates A. The future challenges facing the development of new antimicrobial drugs Nat. Rev. 1 2002 895 910
8. Lax E. The mold in Dr. Florey's coat 2004 Henry Holt and Co. New York
9. Kluger J. Splendid solution 2004 G.P. Putnam's Sons New York